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Cigarette smoking during pregnancy has been
shown to increase the incidence of abortions,
premature deliveries and lighter weight of the
newborns. However, an explicit explanation for
these findings is still lacking and until now it
cannot be excluded that the constitution of the
pregnant woman who smokes might be related
to these observations and not to the smoking
habit per se [2, 5, 11, 24, 32, 33]. Besides these
clinical findings it was demonstrated that in the
term placenta the enzymatic hydroxylation of
benzo(a)pyrene (BP), one of several carci-
nogens present in cigarette smoke, was found
in almost all placentas from women with
smoking habits during pregnancy but no or
only little BP hydroxylase could be detected in
the placentas from nonsmokers [13, 29, 30]. The
relationship of the clinical findings and the
ability of components of cigarette smoke to
stimulate BP hydroxylation by enzymes in the
placenta still remains to be clarified.
The results of these studies have prompted our
laboratory in late 1970 to evaluate whether in the
immature placenta BP hydroxylase activity could
be detected and whether there exists a correlation
between the activity of this enzyme and the
habit of cigarette smoking during the early
phase of pregnancy. Since then, data were
published showing that in the immature placenta
the capacity to metabolize BP was not found in
the placentas from nonsmokers, but the placentas
from smokers metabolized BP, though being
lower in the immature than in the term tissue.
However, no enzyme activity was detectable in
the placenta from smokers before the eleventh
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week of pregnancy [7, 19]. Similarly, in rats the
maximum stimulatory effect by BP treatment on
BP hydroxylase in the placenta was not achieved
before day 15 of gestation [26, 27]. Besides the
above mentioned data, the capacity of enzymes in
the human placenta to metabolize drugs and
foreign compounds is rather limited. Immature
or mature placentas were inactive in metabolizing
hexobarbital, chlorpromazine, codein, aniline,
aminopyrine, amphetamine, p-nitrobenzoic acid
[8], p-nitroanisole, acetaniline, amphetamine,
aniline [3], phenobarbital [29] though N-methyl-
aniline [20] and neoprontisil [8] were found to be
metabolized and 3-methyl-4-monomethylamino-
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azobenzene only in placentas £rom cigarette
smokers [29].
In addition, we investigated whether the fetal
liver is able to hydroxylate BP and to N-demethyl-
ate ethylmorphine. In several laboratories the
existence of drug metabolizing enzyme activity
in the fetal liver has been demonstrated [6,15, 16,
17, 18, 19, 20, 21, 23, 31]. So far, the Substrates
found to be metabolized by fetal liver enzymes
include: Benzo(a)pyrene, N-methylaniline, chlor-
promazine, p-nitrobenzoic acid, aniline, amino-
pyrine, hexobarbital [16, 17, 18, 19, 20, 21]
benzo(a)pyrene, ethylmorphine, aniline [23], lau-
rate and testosterone [31]. The latter authors
were unable to detect any aminopyrine N-
demethylation and benzo(a)pyrene hydroxylation
1
 though they demonstrated the presence of all
components required for the oxidation of drugs,
steroids, and foreign compounds. Furthermore,
no demethylation activity for p-nitroanisol and
N-monomethyl p-nitroaniline could be detected
[22].
This report demonstrates that in the immature
placenta the level of BP hydroxylase activity
does not differ between the smoking and
nonsmoking group and that the fetal liver is
capable of metabolizing BP and ethylmor-
phine.
l Materials and methods
1.1 Tissues:
Placenta and fetal liver were obtained from patients under-
going therapeutic abortion for socio-medical reasons. All
patients received the following premedication and an-
esthesia: Cyclobarbital, 100mg; isothipendyl, 20mg;
fentanyl citrate, 0.10 mg; droperidol, 5.0 mg; atropin,
0.25 mg; succinyldicholine, 100—200 mg; thiopental,
150 mg; and halothane, nitrous oxide, oxygen, and 300—
500 ml of a plasma expander and 300—500 ml of a 5%
glucose solution. Clinical histories were recorded by staff
members of the hospital while one author (E. S.) asked the
women for smoking habits during pregnancy. The duration
of pregnancy was estimated from the last menstrual period.
All patients lived in Berlin. Tissues were obtained from
5 patients by hysterotomy and from 13 patients by curettage.
The tissues obtained during surgery were immediately
frozen in liquid nitrogen and stored in liquid nitrogen until
use within l—5 days. The tissues were than thawed at
room temperature. Two 8 gram samples of one placenta
were dissected from connective tissue. The placenta was
carefully minced and homogenized in ice cold 0.32 M
sucrose-tris HC1 solution (0.01 M tris HC1, pH 7.4). The
whole fetal liver was homogeiaized in the same solution.
Only whole homogenates were employed for the enzyme
assays.
1.2 Enzyme assays:
The following incubation mixturewas used for the mea-
surement of benzo(a)pyrene hydroxylase activity: 5 enzyme
units of glucose-6-phosphate dehydrogenase in 0.05 M tris
HC1 bufFer (pH 7.4); glucose-6-phosphate in 0.05 M tris
HC1 bufFer (pH 7.4), 6,5 ^moles; nicotine adenine di-
nucleotide phosphate (NADP), 0.5//moles; nicotine
adenine dinucleotide (NAD), O.o^moles; ädenosine
triphosphate (ATP), 2.01 /jmoles; NADP, NAD, and ATP
were dissolved in 0.1 M KH2PO4—K2HPO4 bufFer (pH
7.4), nicotinamide, 12^moles; KC1, 200ywmoles; MgQ2,
10/imoles; 1.0ml KHgPO^igHPC^ bufFer (pH 7.4),
benzo(a)pyrene 6.39 X 10~5 M dissolved in 0.1 ml acetone,
and 0.5 ml of placental homogenate equivalent 100—200 rng
wet weight or 0.5 ml fetal liver homogenate equivalent
10—20 mg wet weight. The total volume was 3.1 ml.
Placental homogenates were incubated for 20 min at 37°C
and liver homogenates for 10 min at 37°C.
For the measurement of ethylmorphine N^demethyläse
each incubation flask consisted of the following: 3 enzyme
units of glucose-6-phosphate dehydrogenase, glucose-6-
phosphate, 20/«noles; NADP, 2//moles; nicotinamide,
20/zmoles; MgQ2, lO^moles; semicarbacide HO, 37.5
^moles; KH2PO4—Na2HPO4 bufFer, pH 7.4, 200^moles;
1.0 ml of fetal liver homogenate equivalent to 400 mg wet
weight; ethyl-morphine, 2 10~3 M dissolved in 1.0ml
1.15% KC1, and 1.15% KC1 solution to give a final volume
of 5.0 ml. The reaction mixtures were incubated for 15 min
at 37°C.
For each enzyme assay two blanks were employed. One
blank was incubated with the complete reaction mixture
but without the homogenate and with the Substrate. A
second blank was incubated with the homogenate but with-
out the Substrate. Under these experimental conditions
enzyme activities were linear.
1.3 Analytical procedutes:
Benzo(a)pyrene hydroxylase activity was assayed äs
detailed previously [9, 28]. The hydroxylated metabolite(s)
of benzo(a)pyrene produced during the incubation was
measured with a ZEISS fluorometer, using 3-hydroxy-
benzo(a)pyrene äs a reference. Ethylmorphine N-deme-
thylase activity was measured by the NASH procedure [12]
äs described in the literature [1] with the exception that
1.0ml 50% trichloroacetic acid was added to stop the
reaction.
2 Results
2.1 Enzymatic hydroxylation of benzo(a)-
pyrene in the placenta
The hydroxylation rate o£ benzo(a)pyrene was
measured in the placentas obtained from 9
nonsmokers and from 9 smokers. In both groups
the mean gestational age did not vary consid-
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Tab. I. Benzo(a)pyrene hydroxylase in the immature placenta and benzo(a)pyrene hydroxylase and ethylmorphine N-
demethylase in the fetal liver.
Patient Age
(years)
Duration of
pregnancy
(weeks)
Cigarettes
smoked
daily
Placenta Fetal
BP Hydroxylase BP Hydroxyl-
( g Hydroxy. BP/g/h) se (//g
Hydroxy-BP/
Mean Range g/h)
liver
Ethylmorphine
N-Demethyl-
ase (//g
HCOH/g/h)
nonsmokers
R S.
G.G.
H. M.
A. B.1)
J.K.
C D.2)
H. K.
R. F.
G. H.
Mean ± S.
smokers
R. A.
E.W.
B. D.
G. G.3)
D.M.
R.J.
H. K.4)
X. G.5)
R. S.
Mean i S.
28
39
32
24
33
34
31
31
33
D. 32±4
37
35
20
40
27
35
42
19
32
D. 32±8
10
12
12
12
14
14
14
14
18
13±2
14
14
12
10
12
12
16
10
12
12±2
0
0
0
0
0
0
0
0
0
3—4
3—5
3—5
8—10
10—12
10—20
20
20
25
0.392
0.094
0.180
< 0.050
<0.050
1.510
< 0.050
0.088
< 0.050
0.252±0.489
< 0.050
0.441
0.068
0.379
< 0.050
< 0.050
0.812
1.176
0.228
0.345±0.413
0.174—0.609 —
0.082—0.105 —
0.180—0.180 . 4.007
—
—
1.510—1.510 —
—
0.060—0.116 10.000
3.940
—
0.347—0.534 —
0.068—0.068 —
0.208—0.550 —
—
—
0.730—0.894 0.656
0.915—1.436 —
0.228—0.228 —
—
—
597.00
—
—
—
—722.70
153.00
—
—350.40
—
—
—
435.00
—
—
Five patients received the following daily medications during pregnancy:
1) A. B.: ethinyl estradiol, 0.05 mg or ethinyl estradiol, 0.05 mg and ly^-ethinyl-lQ-nortestorone-acetate, 2.00 mg
2) C. D.: Barbital, 300mg; Phenobarbital, 30mg; Aminophenazone, 18mg; Phenacetin, 200mg; Acetylsalicylic acid,
250 mg; Coffein, 50 mg'
3) G.G.: Trifluoperazine, 2.36 mg; trans-2-phenylcyclopropylaminsulfat, 27.4mg; Methaqualone, 250 mg; Diphenhy-
dramin, 25 mg; Cyproheptadine, 12 mg
4) H. K.: Diphenylhydantoin, 105mg; Phenobarbital, 53mg; Coffein, 90mg; Sodiumbromide, 300mg; Ammonium-
bromide, 75 mg
5) X. G.: Fluphenazine, 2.0 mg.
For experimental details see Materials and Methods; — = not investigated
erably, being 13 and 12 weeks, respectively. The
results of these studies are shown in Tab. I.
In the placentas obtained from nonsmokers only
in four no BP hydroxylase activity could be
detected, i. e. incubation of the placenta with
BP did not result in fluorescence exceeding the
blank values. One of the patients (A. B.) ccidently
received an oral contraceptive. However, in
five of the placentas from nonsmokers BP
hydroxylase activity was detectable. The degree
of BP hydroxylation by enzymes in the placenta
varied 17 fold, ranging from 0.088 μζ 3-Hydroxy-
BP/g tissue/hr (Patient R. F.) to l.SlO^g 3-
Hydroxy-BP/g tissue/hr (Patient C. D.). The
highest enzyme activity was measured in the
placenta of Patient C. D. who was taking high
doses of barbiturates, phenacetin and other drugs
before and during pregnancy. The mean value
of enzyme activity in the placentas from non-
smokers was 0.252 ± 0.489 μξ 3-Hydroxy-BP/g
tissue/hr.
In the placentas from 9 smokers in 3 no metab-
olism of BP was found (patients R. A., D. M.,
R. J.). These women smoked 3 to 4 or more than
10 cigarettes daily. In the other 6 placentas the
rate of BP hydroxylation varied and no corre-
J. Pcrinat. Mecl. 2 (1974)
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lation was found between the daily number of different. In addition, in our experiments the
cigarettes smoked and the level of BP hydroxylase immediate storage of the placenta in liquid
activity. In this group the mean BP hydroxylase nitrogen may prevent the degradation of a labile
activity was 0.344 i 0.413/jg 3-Hydroxy-BP/g form of BP hydroxylase. b) The women of the
tissue/hr. nonsmoking group might have been exposed to
In three placentas obtained during the eleventh foreign compounds or drugs that resulted in
week of pregnancy (from nonsmokers E. S. and elevated levels of BP hydroxylase activity.
from smokers G. G. and X. G.) BP hydroxylase Interestingly, the highest enzyme activity is found
activity was detectable. in the placenta of nonsmoker C. D. who was
With the exception of placentas from non- taking high doses of drugs. Some of these drugs
smokers C. D. and H. M. and from smokers (barbiturates and probably aminophenazone) do
B. D. and R. S. the rate of BP hydroxylation was stimulate various drug metabolizing enzyme
not identical in the two samples of one placenta reactions in man [4]. However, it h s not been
examined. This indicates that this enzyme might established that they enhaiice the hydroxylation
be predominantly localized in distinct areas of the of BP. c) Other factors involved may be genetic
tplacenta. differences in the capacity to metabolize BP and
furthermore variations in the living conditions.
2.2 Enzymatic hydroxylation of benzo(a)- The disproportionate distribution of this enzyme
pyrene and enzymatic N-demethylation found in our expenments indicates a distmct
of ethylmorphine in the fetal liver loca zation within differentiated parts o£ the
_,, r i r τ · ι r o placenta. Recently, regional differences in theThe age of the fetuses obtained from 3 non- . , , . , . . ", ^ t ^ i ·,
,
 Ί Λ , Ί Γ „ Λ Λ, steroid biosynthesis in the mature placenta could
smokers and 2 smokers ranged from 12 to 16 ,
 Ί x , -/- ι ι - i 7 Mm
_ _
 Ί 5? , - berelatedtospecificmorphologicalstructuresflOL
weeks. The results (Tab. I) demonstrate the
 T _ , Γ ι 1 · ι ι - r ,
r .« 4. u i- · Independent of the smoking habits of theexistence of the two metabolizing enzyme / , _ _
 Γ , .
.
 Λ. , . ii ι- Α· mother BP hydroxylase activity was found inreactions studied in a l l liver preparations, \ Jm ' <
, ι τ . .
 £ *, . i all fetal livers investigated. The capacity of thethough large variations were found m the
 r _ n. " , ,. -r^-n. , , Λ . ,
u j i · r -or» j t . r t . 1 fetal hver to metabohze BP and other chemicalshydroxylation rate of BP and the rate of ethyl- _ ._ ; _ .
t ·
 XT i , i .. ,^1 ι τ ΊΊ does not necessanly imply a detoxificationmorphine N-demethvlation. Though only a small , . . _ , _ / r \ , . , ·
i r r Ί v ' · · j « t i mechamsm. Metabolites, produced m the fetal
number of fetal livers was mvestigated, probably . . . r Γ ι ι ·
t ^ ,. . ^ , ^ ^ι_ ι ι Λ tissues and otherwise safe for adult tissues, might
no relationship exists between the level of
 Λ Λ . , . Λ . „ , . Γ . '
δ
 ,
Α. .^· j Λ ^ ι j ^t. ι t be harmful for the rapidlv proliferatms: andenzyme activities and fetal age and the level ,._ . . . , . r J ^ , , . ^
r -DTI t. j i
 A· -x · Ti_ i -L j differentiating fetal tissues. In addition. highlyof BP hydroxylase activity in the placenta and . . δ .. " , ' δ Ί ^£ j j. reactive intermediates, s for exarnple epoxides
deriving from the metabolism of BP and other
chemicals might not be converted rapidly enough
3 Discussion to protect fetal tissues susceptible to the cytotoxic
The results presented in this paper do not effects of these compounds [14].
demonstrate differences in the levels of BP In conclusion, more work is needed to evaluate
hydroxylase activity in the placenta obtained the relevance of the drug metabolizing capacity
from nonsmoking and cigarette smoking of fetal tissues, including the placenta. In addition,
women between the eleventh and nineteenth alterations in maternal drug metabolism may
week of pregnancy. This might suggest that occur in those women who are ' exposed to
components of cigarette smoke have no or only chronic drug administration during pregnancy
a small stimulatory effect on the BP hydroxylation and thus might affect fetal development. Under
rate during this phase of placental development. experimental conditions, chronic phenobarbital
The differences between our results and those treatment of pregnant rats showed markedly
reported in the literature [6, 19] can be related decreased drug metabolizing enzyme activity when
to the following factors: a) The methods used for compared with nonpregnant phenobarbital treated
measuring BP hydroxylase activity were slightly rats [25].
J. Perinat. Mcd. 2 (1974)
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Summary
Benzo(a)pyrene (BP) hydroxylase activity was assayed in
the immature placenta obtained from 9 nonsmoking and
from 9 cigarette smoking women undergoing therapeutic
abortion for socio-medical reasons between the eleventh
and nineteenth week of pregnancy. In the nonsmoking
group the activity o£ this enzyme was not detectable in
4 placentas. In the other 5 placentas the hydroxylation rate
of BP ranged from 0.088 to 1.510//g 3-Hydroxy-BP/g
tissue/h (Tab. I). In the placentas obtained from 9 women
with a history of cigarette smoking 3 had no BP hydroxylase
activity. These women smoked 3 to 20 cigarettes daily. The
other 6 women smoked almost the same daily number of
cigarettes and in the placentas of these individuals the
rate of BP hydroxylation ranged from 0.068 to 1.176//g
3-Hydroxy-BP/g tissue/h. The mean ± S. D. of BP hy-
droxylase activity was 0.252 ± 0.489 and 0.345 ± 0.413 /*g
3-Hydroxy-BP/g tissue/h in the nonsmoking and cigarette
smoking group, respectively. These data suggest that
between the eleventh and nineteenth week of pregnancy
cigarette smoke has no or only a small stimulatory effect on
placental BP hydroxylase activity. Furthermore, other
factors than components of cigarette smoke might enhance
enzymatic BP hydroxylation. For example, the highest
enzyme activity (1.510^g 3-Hydroxy-BP/g tissue/h) was
found in the placenta of a nonsmoker who was taking high
doses of barbiturates and other drugs. — The disproportio-
nate distribution of this enzyme found in our experiments
indicates a distinct localization within difTerentiated parts
of the placenta.
In the fetal liver the activity of enzymes that hydroxylate
BP and N-demethylate ethylmorphine was demonstrated.
No correlation was observed between the levels of BP
hydroxylase activity in the fetal liver and in the placenta.
In fetal tissues the capacity to metabolize drugs and
foreign compounds does not necessarily imply a
detoxification mechanism since metabolites derived
from these reactions might be harmful for the rapidly
proliferating and differentiating fetal tissues.
Keywords: Benzo(a)pyrene hydroxylase, cigarette smoking, human immature placenta, human fetal liver, drug metabolism.
Zusammenfassung
Keine Unterschiede der Aktivitäten von Benzo(a)py-
ren-Hydroxylase in der unreifen menschlichen Pla-
zenta und in der fetalen Leber bei Raucherinnen und
Nichtraucherinnen.
Bei 18 Frauen, 9 Nicht- und 9 Zigarettenraucherinnen,
wurde eine Schwangerschaftsunterbrechung aus sozial-
medizinischen Gründen zwischen der elften und neun-
zehnten Woche durchgeführt. Die Benzo(a)pyren (BP)-
Hydroxylase Aktivität wurde in der Plazenta aller Frauen
bestimmt. In der Gruppe der Nichtraucherinnen war in
4 Plazenten die Aktivität dieses Enzyms nicht nachweisbar,
\vahrend in 5 Plazenten die BP Hydroxylierungsrate 0,088
bis 1,510 % 3-Hydroxy-BP/g Gewebe/Std. betrug (Tab. I).
In der Gruppe der Raucherinnen, die täglich 3 bis 20
Zigaretten rauchten, war in 3 Plazenten die Aktivität der
BP Hydroxylase nicht meßbar. Bei 5 Patientinnen variierte
die Hydroxylierungsrate in der Plazenta von 0,068 bis
1,176/^g 3-Hydroxy-BP/g Gewebe/Std. Der Mittelwert
(± S. D.) der BP Hydroxylaseaktivität betrug 0,252 ±
0,489 ^ g 3-Hydroxy-BP/g Gewebe/Std. in der Gruppe der
Nichtraucherinnen gegenüber 0,345 i 0,413 % 3-Hy-
droxy-BP/g Gewebe/Std. in der Gruppe der Raucherinnen.
Diese Daten zeigen, daß während der elften bis neunzehnten
Woche der Schwangerschaft das Rauchen von Zigaretten
keine oder nur eine geringfügig stimulierende Wirkung
auf die plazentare BP Hydroxylaseaktivität hat. Da die
höchste Enzymaktivität (1,510 § 3-Hydroxy-BP/g Ge-
webe/Std.) in der Plazenta einer Nichtraucherin gefunden
werden konnte, die hohe Dosen an Barbituraten und
anderen Arzneimitteln eingenommen hatte, muß ange-
nommen werden, daß außer den Komponenten des
Zigarettenrauches auch Arzneimittel die BP Hydroxy-
lierungsrate erhöhen können. — Die ungleichmäßige Ver-
teilung der BP Hydroxylaseaktivität in der Plazenta läßt
eine spezifische Lokalisation dieses Enzyms innerhalb
gewisser morphologischer Strukturen vermuten.
In. der fetalen Leber.war sowohl die Hydroxylierung von
BP als auch die N-Demethylierung von Äthylmorphin
nachweisbar. Zwischen der Höhe der BP Hydroxylase-
aktivität in der fetalen Leber und in der Plazenta konnte
keine Korrelation gefunden werden.
Die Fähigkeit der fetalen Gewebe, Arzneimittel und
Fremdstoffe zu metabolisieren, kann nicht zwangs-
läufig als Schutzmechanismus gedeutet werden. Ein
Einfluß der Metaboliten auf embryonale Wachstums-
und Differenzierungsprozesse ist nicht auszuschließen·
Schlüsselwörter: Arzneimittelstofrwechsel, Benzo(a)pyren Hydroxylase, menschliche fetale Leber, menschliche unreife
Plazenta, Zigarettenrauchen.
Resume
Similitude d'activite de Phydroxylase du benzopyrene
au niveau du placenta humain immature et du foie
foetal chez les fumeuses et les non fumeuses
Nous avons evalue Pactivit6 d'hydroxylation du Benzo-
pyrene (BP) chez neuf fumeuses et 9 non fumeuses ayant
subi un avortement therapeutique entre la l lerne et la
19eme semaine de grossesse. Chez les non fumeuses,
Tactivitd de cette enzyme ne put etre mise en evidence dans
4 placentas. Dans les 5 autres placentas, le taux d'hydroxy-
lation du BP fut compris entre 0,088 et 1,510/ig de 3-
Hydroxy-Benzopyrene par gramme de tissu et par heure
(Tab. I). Chez les fumeuses 3 placentas ne montrerent
J. Pcrinat. Mcd. 2 (1974) 14
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aucune activite d'hydroxylation du BP (ces femmes fumaient
de 3 a 20 cigarettes par jour). Chez les 6 autres femmes, qui
fumaient Je meme nombre de cigarettes par jour, on trouva
une activite d'hydroxylation placentaire du BP comprise
entre 0,068 et 1,176 ^ g de 3-Hydroxy-BP par gramme de
tissu par heure. L'activite d'hydroxylation moyenne ± un
ecart type fut respectivement de 0,252 ± 0,489 § de
3-OH-BP/g de tissu/heure chez les non fumeuses et de
0,345 ± 0,413 % de 3-OH-BP/g de tissu/heure chez les
fumeuses.
Ces faits suggerent que la tabagisme a peu ou pas d'in-
fluence sur l'activite hydroxylasique placentaire entre la
lleme et la 19eme semaine de gestation.
Bien plus, d'autres facteurs que les composants de la fumee
de cigarettes peuvent augmenter l'hydroxylation du
Benzopyrene. Par exemple: le taux le plus haut d'activite
(1,510 ^ g 3-OH-BP/g de tissu/heure) fut trouve chez une
non fumeuse prenant de fortes doses de barbituriques et
d'autres drogues.
La distribution variable de cette enzyme dans nos ex-
perimentations montre une localisation particuliere de
l'enzyme d'un endroit a l'autre du placenta.
Nous avons mis en evidence dans le foie foetal, une ac-
tivite enzymatique qui provoque Thydroxylation du BP
et du N-demethylate d'ethylmorphine. Nous n'avons pas
trouve de difference significative d'activite enzymatique
de la BP-hydroxylase entre le foie foetal et la placenta.
Dans les tissus foetaux, la capacite de metaboliser les
drogues et les composes ettangers n'implique pas
necessairement un mecanisme de detoxication vu que
les catabolites de telles teactions pourraient etre
nuisibles a la croissance et a la differenciation des
tissus foetaux.
M ots-cles: Benzopyrene hydroxylase, foie foetal, metabolisme des drogues, placenta humain immatüre, tabagisme.
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